Literature DB >> 27272514

[Malignant hyperthermia syndrome in the intensive care unit : Differential diagnosis and acute measures].

W Grander1.   

Abstract

Malignant hyperthermia is a life-threatening disease caused by derangement of the autonomic nerve system and hypermetabolism of the peripheral musculature. Commonly body core temperatures of more than 40 °C will be found in this disease which is caused mostly by psychopharmacological drugs like antidepressants, neuroleptics but also antibiotics, pain killers, anti-Parkinson drugs, and volatile anesthetics. The inducers of malignant hyperthermia interact with postsynaptic receptors (serotonin, anticholinergics) or muscular intracellular structures responsible for calcium utilization (volatile anesthetics, succinylcholine). Rarely malignant hyperthermia is a consequence of mental stress or vigorous exercise and or heat. Malignant hyperthermic syndromes lead to a severe dysbalance of the autonomic nerve system accompanied by rhabdomyolysis, disseminated intravascular coagulopathy, and finally multi-organ failure. Accordingly, medical management is primarily directed to stabilize vital functions, withdrawal of the causing drug, and if possible antagonizing toxic substances. The leading symptom hyperthermia needs to be treated physically with available cooling systems.

Entities:  

Keywords:  Anesthetics; Fever; Malignant hyperthermia; Neuroleptic malignant syndrome; Rhabdomyolysis

Mesh:

Year:  2016        PMID: 27272514     DOI: 10.1007/s00063-016-0173-9

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  26 in total

1.  Neuroleptic malignant syndrome associated with bromocriptine withdrawal in Parkinson's disease--a case report.

Authors:  Yung-Fu Wu; Yuk-Shing Kan; Chen-Hong Yang
Journal:  Gen Hosp Psychiatry       Date:  2011-01-08       Impact factor: 3.238

2.  A prospective analysis of 24 episodes of neuroleptic malignant syndrome.

Authors:  P Rosebush; T Stewart
Journal:  Am J Psychiatry       Date:  1989-06       Impact factor: 18.112

3.  An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method.

Authors:  Ronald J Gurrera; Stanley N Caroff; Abigail Cohen; Brendan T Carroll; Francis DeRoos; Andrew Francis; Steven Frucht; Sanjay Gupta; James L Levenson; Ahsan Mahmood; Stephan C Mann; Michael A Policastro; Patricia I Rosebush; Henry Rosenberg; Perminder S Sachdev; Julian N Trollor; Varadaraj R Velamoor; Charles B Watson; Jayne R Wilkinson
Journal:  J Clin Psychiatry       Date:  2011-06-28       Impact factor: 4.384

4.  Neuroleptic malignant syndrome: long-term follow-up of 20 cases.

Authors:  H G Pope; H G Aizley; P E Keck; S L McElroy
Journal:  J Clin Psychiatry       Date:  1991-05       Impact factor: 4.384

5.  Propofol impairment of mitochondrial respiration in isolated perfused guinea pig hearts determined by reflectance spectroscopy.

Authors:  K A Schenkman; S Yan
Journal:  Crit Care Med       Date:  2000-01       Impact factor: 7.598

Review 6.  Mortality from neuroleptic malignant syndrome.

Authors:  A Shalev; H Hermesh; H Munitz
Journal:  J Clin Psychiatry       Date:  1989-01       Impact factor: 4.384

Review 7.  The neuroleptic malignant syndrome and its differentiation from lethal catatonia.

Authors:  W W Fleischhacker; B Unterweger; J M Kane; H Hinterhuber
Journal:  Acta Psychiatr Scand       Date:  1990-01       Impact factor: 6.392

8.  Postoperative malignant hyperthermia: an analysis of cases from the North American Malignant Hyperthermia Registry.

Authors:  Ronald S Litman; Christopher D Flood; Richard F Kaplan; Yung Ly Kim; Joseph R Tobin
Journal:  Anesthesiology       Date:  2008-11       Impact factor: 7.892

9.  Multiple anticholinergic medication use and risk of hospital admission for confusion or dementia.

Authors:  Lisa M Kalisch Ellett; Nicole L Pratt; Emmae N Ramsay; John D Barratt; Elizabeth E Roughead
Journal:  J Am Geriatr Soc       Date:  2014-10-03       Impact factor: 5.562

Review 10.  Neuroleptic malignant syndrome. Recognition, prevention and management.

Authors:  V R Velamoor
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

View more
  1 in total

1.  [Prolonged neuroleptic malignant syndrome after Haloperidol injection].

Authors:  N Wystub; S Heymel; M Fritzenwanger; P C Schulze; R Pfeifer
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-07-27       Impact factor: 0.840

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.